{"gene":"KIR2DL4","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":2001,"finding":"KIR2DL4 engagement on resting NK cells induces IFN-γ production but not cytotoxicity, and this IFN-γ induction is blocked by a p38 MAPK inhibitor, placing p38 MAPK downstream of KIR2DL4 signaling; in contrast, CD16 and 2B4 induced cytotoxicity but not IFN-γ, revealing a functional dichotomy dictated by individual receptor signals.","method":"Redirected lysis assay, cytokine ELISA, pharmacological MAPK inhibitors (p38 vs ERK pathway)","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean functional assays with pharmacological pathway dissection, multiple orthogonal readouts in a focused mechanistic study","pmids":["11489965"],"is_preprint":false},{"year":2002,"finding":"The transmembrane arginine-tyrosine motif (not the cytoplasmic ITIM) is required for the activating signal of KIR2DL4; the ITIM tyrosine is dispensable for activation but, when phosphorylated, recruits SHP-1 and SHP-2 (Src homology 2-containing phosphatases), conferring inhibitory potential; an activation-deficient KIR2DL4 mutant can inhibit CD16-mediated signaling.","method":"Site-directed mutagenesis of ITIM tyrosine and transmembrane arginine; redirected lysis assay; GST pull-down with phosphorylated cytoplasmic tail and SHP-1/SHP-2","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro mutagenesis combined with pull-down biochemistry and functional assay in a single rigorous study","pmids":["12055234"],"is_preprint":false},{"year":2003,"finding":"KIR2DL4 engagement triggers potent IFN-γ production but weak cytotoxicity in NK cells; the ITIM does not influence the activating function of the full-length receptor (2DL4.1), and a truncated form lacking the ITIM (2DL4*) shows similar activation potential, confirming the ITIM is not required for activation.","method":"Epitope-tagged receptor transfection into NK-like cell line; antibody cross-linking; cytokine ELISA; redirected lysis assay; comparison of full-length vs. truncated cDNA clones","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple cDNA constructs compared with orthogonal functional readouts (cytokine vs. cytotoxicity), single lab","pmids":["14500636"],"is_preprint":false},{"year":2003,"finding":"The 9A allele of KIR2DL4 (single adenine deletion in the transmembrane exon causing a frameshift and premature stop codon) results in loss of cell-surface expression; only individuals with at least one 10A allele show detectable surface KIR2DL4 and activating function in redirected lysis assays.","method":"Transfection of 10A vs. 9A cDNA into cell lines; surface staining with anti-KIR2DL4 mAb on primary NK cells stratified by genotype; redirected lysis assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genotype-phenotype correlation confirmed by both transfection and primary cell analysis, replicated across multiple donors","pmids":["12902476"],"is_preprint":false},{"year":2005,"finding":"KIR2DL4 associates with FcεRI-γ (FcepsilonRI-gamma) via its transmembrane arginine residue; this association promotes surface expression and provides signal-transducing function. Weak cytolytic responses correlate with low stoichiometric association with γ. This distinguishes KIR2DL4 from all other activating KIRs, which associate with DAP12.","method":"Co-immunoprecipitation; biochemical association assays; functional cytolysis assays; transmembrane arginine mutagenesis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal biochemical evidence plus functional validation with mutagenesis, single lab but multiple orthogonal methods","pmids":["15778339"],"is_preprint":false},{"year":2005,"finding":"The KIR2DL4 promoter drives NK cell-specific reporter gene expression. An inhibitory element upstream of the core promoter suppresses KIR2DL4 promoter activity. AML-2 (RUNX family) binds a conserved AML site in the KIR2DL4 promoter and acts as a repressor; mutation of this site increases promoter activity.","method":"Promoter-reporter transfection assays in NK3.3 cells and primary NK cells; DNase I footprinting; site-directed mutagenesis of transcription factor binding sites; methyltransferase inhibitor treatment","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter dissection with mutagenesis and footprinting in NK cells, single lab","pmids":["15778373"],"is_preprint":false},{"year":2005,"finding":"Residues Met76 and Gln79 in the α1 domain of HLA-G are critical for KIR2DL4 recognition; mutation of both to Ala reduced binding of a KIR2DL4-IgG Fc fusion protein and altered cytolytic function of KIR2DL4-transfected NK-92 cells against HLA-G-expressing targets.","method":"Retroviral transduction of wild-type and mutant HLA-G into K562 cells; KIR2DL4-IgG Fc fusion protein binding assay; cytotoxicity (LDH release) assay with KIR2DL4-transfected NK-92 cells","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis of ligand with binding assay and functional cytotoxicity readout, single lab","pmids":["15780179"],"is_preprint":false},{"year":2007,"finding":"KIR2DL4 encoded by the 9A allele can produce a secreted form of the receptor (lacking the transmembrane domain due to exon skipping); individuals with 10A alleles who lack detectable surface KIR2DL4 express a ΔD0 receptor not recognized by available anti-KIR2DL4 mAbs; surface KIR2DL4 disappears 16 days post-activation despite maintained mRNA, indicating a post-transcriptional negative regulator of surface expression.","method":"RT-PCR analysis of splice variants; flow cytometry with anti-KIR2DL4 mAbs; in vitro NK cell culture and activation assays; genotyping","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple primary donor analyses with orthogonal methods (flow cytometry, RT-PCR, culture assays), single lab","pmids":["17171757"],"is_preprint":false},{"year":2008,"finding":"KIR2DL4 signals through two distinct structural modules: (1) the transmembrane arginine mediates FcεRI-γ association, which is required for cytolytic activity and calcium responses; (2) a second domain independent of the transmembrane arginine activates MAPKs (JNK, ERK, p38), the classical NF-κB pathway (IKKβ phosphorylation, IκBα degradation), and cytokine transcription/translation (TNF-α, IFN-γ, MIP1α, MIP1β, IL-8). MAPK inhibitors (JNK, MEK1/2, p38) block cytokine production in a nonredundant manner.","method":"Site-directed mutagenesis of transmembrane arginine (R/G mutant); receptor cross-linking; Western blot for MAPK phosphorylation and IκBα; pharmacological inhibitors; cytokine ELISA; co-immunoprecipitation for FcεRI-γ","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis plus multiple pathway readouts plus pharmacological dissection in a single rigorous mechanistic study","pmids":["18292514"],"is_preprint":false},{"year":2008,"finding":"Epigenetic status of the KIR2DL4 promoter determines transcriptional competency: NK cells have a fully demethylated KIR2DL4 promoter with active histone marks (H3/H4 acetylation, di/trimethyl H3-Lys4, reduced dimethyl H3-Lys9); aging T cells show partial demethylation and increased dimethyl H3-Lys4 that renders the promoter sensitive to DNMT inhibition, enabling KIR2DL4 transcription.","method":"Bisulfite sequencing of KIR2DL4 promoter; chromatin immunoprecipitation (ChIP) for histone modifications; DNMT inhibitor treatment; RT-PCR for KIR2DL4 expression in sorted T cell subsets","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus bisulfite sequencing plus functional DNMT inhibition, single lab","pmids":["18586981"],"is_preprint":false},{"year":2010,"finding":"KIR2DL4 resides in endosomes rather than on the cell surface of resting NK cells. Soluble HLA-G is internalized into KIR2DL4-positive endosomes, and signaling from this intracellular location triggers a proinflammatory and proangiogenic response via the serine/threonine kinases DNA-PKcs and Akt.","method":"Endosomal fractionation/localization studies; receptor internalization assays; inhibitor studies targeting DNA-PKcs and Akt; cytokine/angiogenic factor readouts (reviewed/summarized mechanistic findings)","journal":"Traffic (Copenhagen, Denmark)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation and localization with functional signaling pathway identification, review article summarizing original experimental findings","pmids":["20854369"],"is_preprint":false},{"year":2012,"finding":"CD158d (KIR2DL4) engagement by agonists triggers a DNA damage response pathway (DNA-PKcs, Akt, NF-κB) and induces cellular senescence in NK cells, characterized by p21 upregulation, HP1-γ phosphorylation, morphological enlargement, survival without cell-cycle entry, and a senescence-associated secretory phenotype (SASP). The secretome of CD158d-stimulated senescent NK cells promoted vascular remodeling and angiogenesis (vascular permeability and endothelial tube formation).","method":"CD158d agonist stimulation of primary NK cells; Western blot for p21 and phospho-HP1-γ; cell morphology analysis; transcriptional profiling (SASP signature); functional assays for vascular permeability and endothelial cell tube formation; retrospective transcriptome analysis of decidual NK cells","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (biochemistry, transcriptomics, cell biology, functional vascular assays) in primary cells with mechanistic pathway identification","pmids":["23184984"],"is_preprint":false},{"year":2012,"finding":"Transcription factors Runx3 and Ets1 bind the KIR2DL4 promoter in situ and are essential for constitutive 2DL4 transcription; two redundant Runx binding sites and a CRE element are required for basal activity. IL-2/IL-15 stimulation increases 2DL4 promoter activity through functional Runx, CRE, and Ets sites.","method":"Promoter mutagenesis; EMSA; cotransfection reporter assays; chromatin immunoprecipitation (ChIP) for Runx3 and Ets1 binding in situ","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis, EMSA, and in situ ChIP confirming transcription factor binding, multiple orthogonal methods in one study","pmids":["22467658"],"is_preprint":false},{"year":2013,"finding":"KIR2DL4 directly interacts with heparan sulfate (HS)/heparin via its D0 domain (identified by genome-wide siRNA screen revealing HS3ST3B1 as a regulator); HS/heparin regulates KIR2DL4-mediated cytokine production; exogenous HS/heparin induces differential KIR2DL4 localization to Rab5+ and Rab7+ endosomes leading to cytokine downregulation and receptor degradation. Syndecan-4 (SDC4) HSPG directly interacts with KIR2DL4 and affects receptor endocytosis and membrane trafficking.","method":"Genome-wide high-throughput siRNA screen; direct binding assays (KIR2DL4–HS/heparin); D0 domain deletion mutant analysis; cytokine ELISA; confocal microscopy for Rab5+/Rab7+ endosomal localization; co-immunoprecipitation (KIR2DL4–syndecan-4)","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide unbiased screen followed by direct binding assays, domain mutagenesis, subcellular localization, and functional cytokine readouts","pmids":["24127555"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of the KIR2DL4 extracellular domains resolved at 2.8 Å reveals a D0-D2 arrangement (no D1 domain) with C2-type immunoglobulin folds and an acute elbow angle. KIR2DL4 self-associates via the D0 domain in a concentration-dependent manner, forming a tetramer in the crystal lattice confirmed by size exclusion chromatography, dynamic light scattering, analytical ultracentrifugation, and SAXS. D0 residues required for tetramer formation preclude an HLA-binding mode akin to KIR3DL1; no direct HLA interaction was detected in binding studies.","method":"X-ray crystallography (2.8 Å); size exclusion chromatography; dynamic light scattering; analytical ultracentrifugation; small-angle X-ray scattering (SAXS); direct HLA binding studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure validated by four independent biophysical techniques, rigorous mechanistic conclusions about self-association and HLA binding","pmids":["25759384"],"is_preprint":false},{"year":2021,"finding":"KIR2DL4 forms a regulatory circuit with the IFN-γ pathway: IFN-γ upregulates KIR2DL4 expression via JAK2/STAT1 signaling, and KIR2DL4 in turn synergizes with Fcγ receptor to increase IFN-γ secretion by NK cells. HLA-G binding to KIR2DL4 desensitizes NK cells to trastuzumab by disrupting antibody-dependent cell-mediated cytotoxicity (ADCC). Blockade of HLA-G/KIR2DL4 signaling restored NK cell cytotoxicity against HER2+ breast cancer in vivo.","method":"Co-culture assays; NK cell cytotoxicity assays; JAK2/STAT1 pathway inhibition; anti-KIR2DL4/HLA-G blocking antibodies; in vivo xenograft mouse model; cytokine ELISA (IFN-γ, TGF-β)","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional pathway dissection with pathway inhibitors and in vivo model, single lab","pmids":["34158475"],"is_preprint":false},{"year":2018,"finding":"KIR2DL4 expressed on NK cells interacts with HLA-G expressed on oligodendrocytes; this KIR2DL4–HLA-G interaction is required for NK-cell-mediated IFN-γ polarization toward oligodendrocytes, which in turn reduces myelin oligodendrocyte glycoprotein (MOG) and myelin associated glycoprotein (MAG) content. This activity is independent of KIR2DL1-mediated MHC class I inhibition.","method":"NK cell–oligodendrocyte conjugate assay; intracellular cytokine staining for IFN-γ; anti-KIR2DL4 blocking antibody; Western blot for MOG and MAG; flow cytometry for KIR2DL4+ NK cell frequency","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — blocking antibody epistasis experiment with functional protein-level readouts, single lab","pmids":["30482463"],"is_preprint":false},{"year":2020,"finding":"KIR2DL4 is expressed on human mast cells (peripheral blood-derived and LAD2 cell line). Agonistic antibodies to KIR2DL4 negatively regulate KIT-mediated and FcεRI-mediated mast cell responses. HLA-G (natural KIR2DL4 ligand) and agonistic antibodies induce secretion of leukemia inhibitory factor and serine proteases from human mast cells.","method":"Flow cytometry for KIR2DL4 on mast cells; agonistic anti-KIR2DL4 antibody stimulation; functional assays for KIT-mediated and FcεRI-mediated responses; ELISA for leukemia inhibitory factor and serine proteases","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — clean functional assays in both primary cells and cell line with defined receptor manipulation, single lab","pmids":["32023940"],"is_preprint":false},{"year":2022,"finding":"KIR2DL4 is expressed in renal cell carcinoma (RCC) cells and promotes RCC cell proliferation; knockdown reduces proliferation/viability while overexpression promotes it in vitro and in vivo. The mechanism involves activation of the PI3K/Akt signaling pathway, as AKT phosphorylation levels correlate with KIR2DL4 expression levels, and combined PI3K inhibitor (wortmannin) plus KIR2DL4-shRNA further reduces phospho-AKT and proliferation.","method":"MTT viability assay; soft agar colony formation; KIR2DL4 knockdown (shRNA) and overexpression; xenograft mouse model; RNA sequencing; Western blot for phospho-AKT; PI3K inhibitor (wortmannin) treatment","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO/OE with in vitro and in vivo readouts plus RNA-seq and pharmacological pathway confirmation, single lab","pmids":["35063466"],"is_preprint":false},{"year":2026,"finding":"Soluble HLA-G activates transcription of type I interferon-stimulated genes (ISGs) in primary NK cells through KIR2DL4 via a noncanonical pathway requiring transcription factor IRF7 and kinase JAK1. The C-terminal portion of the KIR2DL4 cytoplasmic tail contains a sequence analogous to conserved JAK1 binding sites in IFN receptors and is required for JAK1 binding to KIR2DL4. HLA-G stimulation leads to nuclear phosphorylation of IRF7 and JAK substrate STAT2, linking KIR2DL4 signaling to ISG transcription. scRNA-seq showed HLA-G induces a broader response in CD56bright than CD56dim NK cells, and ISG expression was detected at the early maternal-fetal interface.","method":"Primary NK cell stimulation with soluble HLA-G vs. agonistic anti-KIR2DL4 antibody; RNA-seq and scRNA-seq; pharmacological JAK1 inhibition; cytoplasmic tail mutagenesis/deletion constructs; co-immunoprecipitation (KIR2DL4–JAK1); Western blot for nuclear phospho-IRF7 and phospho-STAT2; comparison with decidual NK scRNA-seq dataset","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis, co-IP, pharmacological inhibition, nuclear phosphorylation detection, and transcriptomic validation in primary cells with multiple orthogonal methods","pmids":["41632833"],"is_preprint":false},{"year":2009,"finding":"In decidual NK (dNK) cells, KIR2DL4 surface expression is controlled by the 9A/10A transmembrane polymorphism (as in peripheral blood NK cells). Freshly isolated dNK cells do not secrete IFN-γ in response to KIR2DL4 ligation regardless of genotype, but IL-2 activation in vitro enables IFN-γ secretion only in donors with at least one 10A allele.","method":"Flow cytometry for KIR2DL4 surface expression on freshly isolated decidual NK cells; anti-KIR2DL4 ligation; IFN-γ ELISA; genotyping for 9A/10A polymorphism","journal":"Molecular human reproduction","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct functional assay on primary decidual NK cells stratified by genotype, single lab","pmids":["19509110"],"is_preprint":false}],"current_model":"KIR2DL4 (CD158d) is an endosome-resident NK cell receptor with a unique D0-D2 extracellular structure that self-associates via D0; it signals through two structural modules—a transmembrane arginine that recruits FcεRI-γ (mediating cytotoxicity/calcium responses) and a second receptor domain that independently activates MAPKs and NF-κB for cytokine production—with soluble HLA-G binding triggering endosomal signaling via DNA-PKcs, Akt, NF-κB, and a noncanonical JAK1-IRF7-STAT2 pathway that drives type I interferon-stimulated gene transcription; the cytoplasmic ITIM can recruit SHP-1/SHP-2 when phosphorylated (conferring inhibitory potential), its expression is regulated epigenetically by promoter methylation and by Runx3/Ets1 transcription factors, and its 9A/10A allelic polymorphism determines whether a membrane-anchored or secreted receptor is produced; additional ligands include heparan sulfate proteoglycans (via the D0 domain), and KIR2DL4 signaling can induce NK cell senescence with a proangiogenic secretory phenotype relevant to vascular remodeling at the maternal-fetal interface, as well as PI3K/Akt-dependent proliferative signaling in renal cell carcinoma cells."},"narrative":{"mechanistic_narrative":"KIR2DL4 (CD158d) is an NK-cell receptor that, unlike its inhibitory KIR relatives, principally drives cytokine production rather than cytotoxicity, inducing IFN-γ and other proinflammatory mediators through MAPK- and NF-κB-dependent signaling [PMID:11489965, PMID:18292514]. It signals through two structurally separable modules: a transmembrane arginine that recruits the FcεRI-γ adaptor to support cytolytic and calcium responses, and a second arginine-independent module that activates JNK, ERK, p38, and the IKKβ–IκBα–NF-κB axis to drive cytokine transcription [PMID:15778339, PMID:18292514]. Its cytoplasmic ITIM is dispensable for activation but, when phosphorylated, recruits SHP-1 and SHP-2 to confer inhibitory potential [PMID:12055234]. KIR2DL4 resides predominantly in endosomes of resting NK cells, where internalized soluble HLA-G triggers signaling via DNA-PKcs, Akt, and NF-κB, and through a noncanonical JAK1–IRF7–STAT2 cascade—JAK1 binding to an IFN-receptor-like sequence in the cytoplasmic tail—that drives type I interferon-stimulated gene transcription [PMID:20854369, PMID:41632833]. The crystal structure reveals an unusual D0–D2 architecture that self-associates into tetramers through the D0 domain, the same domain that binds heparan sulfate proteoglycans and syndecan-4 to modulate endosomal trafficking and cytokine output [PMID:24127555, PMID:25759384]. Engagement induces an NK-cell senescence program with a proangiogenic secretory phenotype relevant to vascular remodeling at the maternal-fetal interface [PMID:23184984]. Expression is governed by 9A/10A transmembrane polymorphism determining membrane versus secreted receptor [PMID:12902476, PMID:17171757], by promoter DNA methylation and histone marks, and by Runx3/Ets1 transcription factors [PMID:18586981, PMID:22467658].","teleology":[{"year":2001,"claim":"Established that KIR2DL4 engagement uncouples cytokine production from cytotoxicity, defining it as a functionally distinct NK receptor whose signal selectively drives IFN-γ via p38 MAPK.","evidence":"Redirected lysis and cytokine ELISA with pharmacological MAPK inhibitors on resting NK cells","pmids":["11489965"],"confidence":"High","gaps":["Did not identify the membrane adaptor or proximal signaling module","Mechanism of selective IFN-γ induction unresolved"]},{"year":2002,"claim":"Mapped the activating signal to a transmembrane arginine-tyrosine motif and showed the ITIM is dispensable for activation but recruits SHP-1/SHP-2 when phosphorylated, defining a dual activating/inhibitory potential.","evidence":"Site-directed mutagenesis, GST pull-down with phospho-tail, redirected lysis","pmids":["12055234"],"confidence":"High","gaps":["Identity of the transmembrane-associated adaptor not yet defined","Physiological conditions favoring inhibitory vs activating output unknown"]},{"year":2003,"claim":"Confirmed the ITIM is not required for the activating function across full-length and truncated isoforms, and showed the 9A frameshift allele abolishes surface expression, linking allelic polymorphism to receptor availability.","evidence":"cDNA construct comparison, surface staining of genotype-stratified primary NK cells, redirected lysis","pmids":["14500636","12902476"],"confidence":"High","gaps":["Fate of the 9A transcript product not characterized at this stage","Post-transcriptional control of surface expression not addressed"]},{"year":2005,"claim":"Identified FcεRI-γ as the adaptor recruited via the transmembrane arginine, distinguishing KIR2DL4 from DAP12-associated activating KIRs, and located the HLA-G recognition determinants and a RUNX-based promoter repressor.","evidence":"Co-IP and mutagenesis for FcεRI-γ; HLA-G α1 mutagenesis with Fc-fusion binding and cytotoxicity; promoter reporter, footprinting, and AML-2 site mutation","pmids":["15778339","15780179","15778373"],"confidence":"High","gaps":["Stoichiometry of γ association versus signaling output incompletely defined","Later structural work questioned direct HLA-G binding"]},{"year":2007,"claim":"Resolved isoform complexity by showing the 9A allele yields a secreted receptor and that surface expression is lost post-activation despite stable mRNA, revealing post-transcriptional control of surface display.","evidence":"RT-PCR of splice variants, flow cytometry, in vitro NK activation, genotyping","pmids":["17171757"],"confidence":"Medium","gaps":["Identity of the post-transcriptional negative regulator unknown","Function of the secreted/ΔD0 forms not established"]},{"year":2008,"claim":"Defined two structurally separable signaling modules—arginine/FcεRI-γ for cytolysis and calcium, and an arginine-independent module for MAPK/NF-κB-driven cytokine production—and showed transcriptional licensing depends on promoter methylation and histone state.","evidence":"Arginine mutagenesis, Western blot for MAPK/IκBα, pharmacological inhibitors, cytokine ELISA; bisulfite sequencing and ChIP for histone marks","pmids":["18292514","18586981"],"confidence":"High","gaps":["Molecular identity of the second signaling module's proximal effector unclear","How the two modules are coordinately engaged by ligand not defined"]},{"year":2009,"claim":"Extended the 9A/10A genotype-phenotype relationship to decidual NK cells and showed IL-2 activation is required to license IFN-γ responses in 10A donors, linking receptor function to the tissue context.","evidence":"Flow cytometry, anti-KIR2DL4 ligation, IFN-γ ELISA on genotyped decidual NK cells","pmids":["19509110"],"confidence":"Medium","gaps":["Mechanism of IL-2-dependent licensing not defined","Endogenous decidual ligand engagement not directly demonstrated"]},{"year":2010,"claim":"Relocalized the receptor's signaling platform to endosomes, showing soluble HLA-G is internalized and signals from this intracellular compartment via DNA-PKcs and Akt to a proinflammatory/proangiogenic output.","evidence":"Endosomal fractionation, internalization assays, DNA-PKcs/Akt inhibitor studies","pmids":["20854369"],"confidence":"Medium","gaps":["Review summary of original data","How endosomal targeting selects signaling output not detailed"]},{"year":2012,"claim":"Connected endosomal KIR2DL4 signaling to a DNA-damage-response-driven NK senescence program with a proangiogenic secretome relevant to maternal-fetal vascular remodeling, and defined Runx3/Ets1 as essential activators of constitutive transcription.","evidence":"CD158d agonist stimulation, p21/phospho-HP1-γ Westerns, SASP profiling, vascular permeability and tube formation assays; promoter mutagenesis, EMSA, ChIP for Runx3/Ets1","pmids":["23184984","22467658"],"confidence":"High","gaps":["In vivo contribution to placentation not directly established","Link between senescence induction and the two signaling modules unresolved"]},{"year":2013,"claim":"Identified heparan sulfate proteoglycans, including syndecan-4, as D0-domain ligands that direct receptor trafficking to Rab5/Rab7 endosomes and tune cytokine output and degradation.","evidence":"Genome-wide siRNA screen (HS3ST3B1), direct binding assays, D0 deletion mutants, confocal Rab5/Rab7 localization, KIR2DL4–syndecan-4 co-IP, cytokine ELISA","pmids":["24127555"],"confidence":"High","gaps":["Relative physiological roles of HSPG versus HLA-G ligation unclear","Whether HSPG binding initiates signaling or only modulates trafficking not fully resolved"]},{"year":2015,"claim":"Determined the extracellular structure as a D0–D2 arrangement that self-associates into D0-mediated tetramers and showed D0 residues required for oligomerization preclude a classical HLA-binding mode, challenging direct HLA-G recognition.","evidence":"2.8 Å crystal structure validated by SEC, DLS, AUC, SAXS, and direct HLA binding studies","pmids":["25759384"],"confidence":"High","gaps":["Reconciliation with prior HLA-G functional data not achieved","Functional consequence of tetramerization for signaling not tested"]},{"year":2018,"claim":"Demonstrated a non-canonical functional context in which NK KIR2DL4 engaging oligodendrocyte HLA-G drives IFN-γ polarization that reduces myelin protein content, independent of KIR2DL1-mediated MHC inhibition.","evidence":"NK-oligodendrocyte conjugate assay, intracellular IFN-γ staining, anti-KIR2DL4 blockade, MOG/MAG Westerns","pmids":["30482463"],"confidence":"Medium","gaps":["Signaling module responsible not dissected","In vivo relevance to demyelinating disease not shown"]},{"year":2020,"claim":"Showed KIR2DL4 expression and function extend beyond NK cells to mast cells, where agonism modulates KIT- and FcεRI-mediated responses and induces secretion of LIF and serine proteases.","evidence":"Flow cytometry and agonistic antibody stimulation of primary and LAD2 mast cells, functional response assays, ELISA","pmids":["32023940"],"confidence":"Medium","gaps":["Signaling pathway in mast cells not mapped","Physiological mast-cell ligand context not defined"]},{"year":2021,"claim":"Defined a feed-forward circuit in which IFN-γ upregulates KIR2DL4 via JAK2/STAT1 and KIR2DL4 synergizes with FcγR for IFN-γ secretion, and showed HLA-G/KIR2DL4 engagement suppresses ADCC against HER2+ tumors that blockade restores.","evidence":"Co-culture and cytotoxicity assays, JAK2/STAT1 inhibition, blocking antibodies, xenograft model, cytokine ELISA","pmids":["34158475"],"confidence":"Medium","gaps":["Single-lab in vivo model","Mechanism by which HLA-G ligation desensitizes ADCC not fully resolved"]},{"year":2022,"claim":"Showed an intrinsic tumor-cell role for KIR2DL4 in renal cell carcinoma, promoting proliferation through PI3K/Akt signaling, distinct from its immune-receptor function.","evidence":"shRNA knockdown and overexpression, MTT and soft agar assays, xenograft, RNA-seq, phospho-AKT Westerns, wortmannin treatment","pmids":["35063466"],"confidence":"Medium","gaps":["Upstream ligand/activation in tumor cells unknown","Single-lab finding in one cancer type"]},{"year":2026,"claim":"Resolved a non-canonical interferon-like signaling mechanism in which the KIR2DL4 cytoplasmic tail binds JAK1 through an IFN-receptor-like sequence and, upon soluble HLA-G binding, drives IRF7/STAT2 nuclear phosphorylation and type I ISG transcription, preferentially in CD56bright NK cells.","evidence":"Soluble HLA-G vs agonist stimulation, RNA-seq/scRNA-seq, JAK1 inhibition, tail mutagenesis, KIR2DL4–JAK1 co-IP, nuclear phospho-IRF7/STAT2 Westerns","pmids":["41632833"],"confidence":"High","gaps":["How JAK1–IRF7–STAT2 integrates with the MAPK/NF-κB and DNA-PKcs/Akt arms unclear","In vivo function of ISG induction at the maternal-fetal interface not established"]},{"year":null,"claim":"It remains unresolved how the structurally distinct signaling modules (FcεRI-γ/cytolytic, MAPK/NF-κB cytokine, DNA-PKcs/Akt senescence, JAK1/IRF7/STAT2 interferon) and the multiple ligands (HLA-G, HSPGs) are coordinately selected to produce a given functional outcome.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking ligand identity, endosomal localization, and output module","Reconciliation of structural absence of HLA-G binding with functional HLA-G responses unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,8,19]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[6,19]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,1]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[13]}],"localization":[{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[10,13]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,4]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,8,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,10,19]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[11]}],"complexes":[],"partners":["FCER1G","HLA-G","PTPN6","PTPN11","SDC4","JAK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99706","full_name":"Killer cell immunoglobulin-like receptor 2DL4","aliases":["CD158 antigen-like family member D","G9P","Killer cell inhibitory receptor 103AS","KIR-103AS","MHC class I NK cell receptor KIR103AS"],"length_aa":377,"mass_kda":41.5,"function":"Receptor for non-classical major histocompatibility class Ib HLA-G molecules. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M). In decidual NK cells, binds peptide-bound HLA-G-B2M complex and triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:23184984, PubMed:29262349). May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:16366734). Upon interaction with peptide-bound HLA-G-B2M, initiates signaling from the endosomal compartment leading to downstream activation of PRKDC-XRCC5 and AKT1, and ultimately triggering NF-kappa-B-dependent pro-inflammatory response (PubMed:20179272)","subcellular_location":"Cell membrane; Early endosome membrane","url":"https://www.uniprot.org/uniprotkb/Q99706/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KIR2DL4","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KIR2DL4","total_profiled":1310},"omim":[{"mim_id":"620778","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, SHORT CYTOPLASMIC TAIL, 1; KIR3DS1","url":"https://www.omim.org/entry/620778"},{"mim_id":"615727","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 5B; KIR2DL5B","url":"https://www.omim.org/entry/615727"},{"mim_id":"610604","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, PSEUDOGENE 1; KIR3DP1","url":"https://www.omim.org/entry/610604"},{"mim_id":"610095","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, LONG CYTOPLASMIC TAIL, 3; KIR3DL3","url":"https://www.omim.org/entry/610095"},{"mim_id":"605305","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 5A; KIR2DL5A","url":"https://www.omim.org/entry/605305"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":4.3}],"url":"https://www.proteinatlas.org/search/KIR2DL4"},"hgnc":{"alias_symbol":["103AS","15.212","CD158D"],"prev_symbol":[]},"alphafold":{"accession":"Q99706","domains":[{"cath_id":"2.60.40.10","chopping":"31-119","consensus_level":"high","plddt":87.5343,"start":31,"end":119},{"cath_id":"2.60.40.10","chopping":"124-217","consensus_level":"high","plddt":94.9969,"start":124,"end":217}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99706","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99706-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99706-F1-predicted_aligned_error_v6.png","plddt_mean":69.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KIR2DL4","jax_strain_url":"https://www.jax.org/strain/search?query=KIR2DL4"},"sequence":{"accession":"Q99706","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99706.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99706/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99706"}},"corpus_meta":[{"pmid":"15670976","id":"PMC_15670976","title":"HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells.","date":"2005","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15670976","citation_count":246,"is_preprint":false},{"pmid":"12055234","id":"PMC_12055234","title":"KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12055234","citation_count":192,"is_preprint":false},{"pmid":"11489965","id":"PMC_11489965","title":"Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11489965","citation_count":188,"is_preprint":false},{"pmid":"22934097","id":"PMC_22934097","title":"KIR2DL4 (CD158d): An activation receptor for HLA-G.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22934097","citation_count":152,"is_preprint":false},{"pmid":"23184984","id":"PMC_23184984","title":"Cellular senescence induced by CD158d reprograms natural killer cells to promote vascular remodeling.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23184984","citation_count":139,"is_preprint":false},{"pmid":"14500636","id":"PMC_14500636","title":"KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14500636","citation_count":139,"is_preprint":false},{"pmid":"15778339","id":"PMC_15778339","title":"Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15778339","citation_count":111,"is_preprint":false},{"pmid":"12902476","id":"PMC_12902476","title":"KIR2DL4 (CD158d) genotype influences expression and function in NK cells.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12902476","citation_count":98,"is_preprint":false},{"pmid":"34158475","id":"PMC_34158475","title":"Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34158475","citation_count":93,"is_preprint":false},{"pmid":"15780179","id":"PMC_15780179","title":"Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition.","date":"2005","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15780179","citation_count":77,"is_preprint":false},{"pmid":"15778373","id":"PMC_15778373","title":"Three structurally and functionally divergent kinds of promoters regulate expression of clonally distributed killer cell Ig-like receptors (KIR), of KIR2DL4, and of KIR3DL3.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15778373","citation_count":67,"is_preprint":false},{"pmid":"15580659","id":"PMC_15580659","title":"The silent KIR3DP1 gene (CD158c) is transcribed and might encode a secreted receptor in a minority of humans, in whom the KIR3DP1, KIR2DL4 and KIR3DL1/KIR3DS1 genes are duplicated.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15580659","citation_count":66,"is_preprint":false},{"pmid":"17171757","id":"PMC_17171757","title":"Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17171757","citation_count":54,"is_preprint":false},{"pmid":"12616484","id":"PMC_12616484","title":"Recognition of HLA-G by the NK cell receptor KIR2DL4 is not essential for human reproduction.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12616484","citation_count":52,"is_preprint":false},{"pmid":"20854369","id":"PMC_20854369","title":"Endosomal signaling and a novel pathway defined by the natural killer receptor KIR2DL4 (CD158d).","date":"2010","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/20854369","citation_count":46,"is_preprint":false},{"pmid":"17362384","id":"PMC_17362384","title":"Possible roles of KIR2DL4 expression on uNK cells in human pregnancy.","date":"2007","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/17362384","citation_count":46,"is_preprint":false},{"pmid":"11754000","id":"PMC_11754000","title":"Alleles of the KIR2DL4 receptor and their lack of association with pre-eclampsia.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11754000","citation_count":44,"is_preprint":false},{"pmid":"12794136","id":"PMC_12794136","title":"Different and divergent regulation of the KIR2DL4 and KIR3DL1 promoters.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12794136","citation_count":43,"is_preprint":false},{"pmid":"11034561","id":"PMC_11034561","title":"Detection of KIR2DL4 alleles by sequencing and SSCP reveals a common allele with a shortened cytoplasmic tail.","date":"2000","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11034561","citation_count":40,"is_preprint":false},{"pmid":"24127555","id":"PMC_24127555","title":"Genome-wide siRNA screen reveals a new cellular partner of NK cell receptor KIR2DL4: heparan sulfate directly modulates KIR2DL4-mediated responses.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24127555","citation_count":36,"is_preprint":false},{"pmid":"25759384","id":"PMC_25759384","title":"The structure of the atypical killer cell immunoglobulin-like receptor, KIR2DL4.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25759384","citation_count":33,"is_preprint":false},{"pmid":"18292514","id":"PMC_18292514","title":"KIR2DL4 differentially signals downstream functions in human NK cells through distinct structural modules.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18292514","citation_count":31,"is_preprint":false},{"pmid":"35185887","id":"PMC_35185887","title":"Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35185887","citation_count":30,"is_preprint":false},{"pmid":"18586981","id":"PMC_18586981","title":"Epigenetic mechanisms of age-dependent KIR2DL4 expression in T cells.","date":"2008","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/18586981","citation_count":28,"is_preprint":false},{"pmid":"14700593","id":"PMC_14700593","title":"Investigation of killer cell immunoglobulinlike receptor gene diversity: I. KIR2DL4.","date":"2004","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14700593","citation_count":28,"is_preprint":false},{"pmid":"25855135","id":"PMC_25855135","title":"Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer.","date":"2015","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/25855135","citation_count":27,"is_preprint":false},{"pmid":"19509110","id":"PMC_19509110","title":"The genotype of the NK cell receptor, KIR2DL4, influences INFgamma secretion by decidual natural killer cells.","date":"2009","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19509110","citation_count":25,"is_preprint":false},{"pmid":"32711226","id":"PMC_32711226","title":"Possible roles of HLA-G regulating immune cells in pregnancy and endometrial diseases via KIR2DL4.","date":"2020","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32711226","citation_count":21,"is_preprint":false},{"pmid":"18314122","id":"PMC_18314122","title":"Human leukocyte antigen-G, a ligand for the natural killer receptor KIR2DL4, is expressed by eutopic endometrium only in the menstrual phase.","date":"2008","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/18314122","citation_count":21,"is_preprint":false},{"pmid":"26973020","id":"PMC_26973020","title":"Possible Role of HLA-G, LILRB1 and KIR2DL4 Gene Polymorphisms in Spontaneous Miscarriage.","date":"2016","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/26973020","citation_count":20,"is_preprint":false},{"pmid":"19700612","id":"PMC_19700612","title":"Possible gene-gene interaction of KIR2DL4 with its cognate ligand HLA-G in modulating risk for preeclampsia.","date":"2009","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/19700612","citation_count":19,"is_preprint":false},{"pmid":"15853895","id":"PMC_15853895","title":"Genomic characterization of KIR2DL4 in families and unrelated individuals reveals extensive diversity in exon and intron sequences including a common frameshift variation occurring in several alleles.","date":"2005","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/15853895","citation_count":18,"is_preprint":false},{"pmid":"19506858","id":"PMC_19506858","title":"Evidence for balancing selection acting on KIR2DL4 genotypes in rhesus macaques of Indian origin.","date":"2009","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19506858","citation_count":17,"is_preprint":false},{"pmid":"32023940","id":"PMC_32023940","title":"Killer Immunoglobulin-Like Receptor 2DL4 (CD158d) Regulates Human Mast Cells both Positively and Negatively: Possible Roles in Pregnancy and Cancer Metastasis.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32023940","citation_count":15,"is_preprint":false},{"pmid":"16573558","id":"PMC_16573558","title":"Investigation of killer cell immunoglobulin-like receptor KIR2DL4 diversity by sequence-based typing in Chinese population.","date":"2006","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/16573558","citation_count":13,"is_preprint":false},{"pmid":"23449795","id":"PMC_23449795","title":"KIR2DL4 copy number variation is associated with CD4+ T-cell depletion and function of cytokine-producing NK cell subsets in SIV-infected Mamu-A*01-negative rhesus macaques.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/23449795","citation_count":13,"is_preprint":false},{"pmid":"16487070","id":"PMC_16487070","title":"Rapid production of human KIR2DL4 extracellular domain and verification of its interaction with HLA-G.","date":"2006","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/16487070","citation_count":12,"is_preprint":false},{"pmid":"35063466","id":"PMC_35063466","title":"KIR2DL4 promotes the proliferation of RCC cell associated with PI3K/Akt signaling activation.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35063466","citation_count":10,"is_preprint":false},{"pmid":"21623736","id":"PMC_21623736","title":"Lack of KIR2DL4 gene in a fertile Caucasian woman.","date":"2011","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/21623736","citation_count":10,"is_preprint":false},{"pmid":"18082267","id":"PMC_18082267","title":"The elucidation of KIR2DL4 gene polymorphism.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18082267","citation_count":10,"is_preprint":false},{"pmid":"28817184","id":"PMC_28817184","title":"The Influence of Cytomegalovirus on Expression of HLA-G and its Ligand KIR2DL4 by Human Peripheral Blood Leucocyte Subsets.","date":"2017","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28817184","citation_count":10,"is_preprint":false},{"pmid":"17610421","id":"PMC_17610421","title":"Allelic diversity in KIR2DL4 in a bone marrow transplant population: description of three novel alleles.","date":"2007","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/17610421","citation_count":10,"is_preprint":false},{"pmid":"30482463","id":"PMC_30482463","title":"KIR2DL4-HLAG interaction at human NK cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects.","date":"2018","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30482463","citation_count":8,"is_preprint":false},{"pmid":"22467658","id":"PMC_22467658","title":"Differential transcription factor use by the KIR2DL4 promoter under constitutive and IL-2/15-treated conditions.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22467658","citation_count":8,"is_preprint":false},{"pmid":"39144721","id":"PMC_39144721","title":"Combined maternal KIR2DL4 and fetal HLA-G polymorphisms were associated with preeclampsia in a Han Chinese population.","date":"2024","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39144721","citation_count":7,"is_preprint":false},{"pmid":"25818657","id":"PMC_25818657","title":"Genetic polymorphism of KIR2DL4 in the Polish population.","date":"2015","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/25818657","citation_count":7,"is_preprint":false},{"pmid":"17498270","id":"PMC_17498270","title":"Enrichment of individual KIR2DL4 sequences from genomic DNA using long-template PCR and allele-specific hybridization to magnetic bead-bound oligonucleotide probes.","date":"2007","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/17498270","citation_count":7,"is_preprint":false},{"pmid":"25033772","id":"PMC_25033772","title":"Two new cases of KIR3DP1, KIR2DL4-negative genotypes, one of which is also lacking KIR3DL2.","date":"2014","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/25033772","citation_count":7,"is_preprint":false},{"pmid":"19679155","id":"PMC_19679155","title":"High levels of molecular polymorphism at the KIR2DL4 locus in French and Congolese populations: impact for anthropology and clinical studies.","date":"2009","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19679155","citation_count":7,"is_preprint":false},{"pmid":"17445175","id":"PMC_17445175","title":"Cloning and sequencing alleles of the KIR2DL4 gene from genomic DNA samples.","date":"2007","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/17445175","citation_count":6,"is_preprint":false},{"pmid":"36890645","id":"PMC_36890645","title":"KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.","date":"2023","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/36890645","citation_count":5,"is_preprint":false},{"pmid":"19304328","id":"PMC_19304328","title":"KIR2DL4 (CD158d) polymorphisms and susceptibility to multiple sclerosis.","date":"2009","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/19304328","citation_count":5,"is_preprint":false},{"pmid":"24033084","id":"PMC_24033084","title":"Genetic polymorphism of KIR2DL4 (CD158d), a putative NK cell receptor for HLA-G, does not influence susceptibility to asthma.","date":"2013","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/24033084","citation_count":5,"is_preprint":false},{"pmid":"37027073","id":"PMC_37027073","title":"The effects of KIR2DL4 stimulated NK-92 cells on the apoptotic pathways of HER2 + /HER-breast cancer cells.","date":"2023","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37027073","citation_count":5,"is_preprint":false},{"pmid":"33305671","id":"PMC_33305671","title":"Expression of HLA-G and KIR2DL4 receptor in chorionic villous in missed abortion.","date":"2020","source":"Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33305671","citation_count":3,"is_preprint":false},{"pmid":"33595694","id":"PMC_33595694","title":"KIR2DL4 genetic diversity in a Brazilian population sample: implications for transcription regulation and protein diversity in samples with different ancestry backgrounds.","date":"2021","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33595694","citation_count":2,"is_preprint":false},{"pmid":"40549069","id":"PMC_40549069","title":"Emerging roles of KIR2DL4 in cancer immunotherapy.","date":"2025","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/40549069","citation_count":1,"is_preprint":false},{"pmid":"26823774","id":"PMC_26823774","title":"KIR2DL4 expression rather than its single nucleotide polymorphisms correlates with pre-eclampsia.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26823774","citation_count":1,"is_preprint":false},{"pmid":"26917249","id":"PMC_26917249","title":"Description of the novel KIR2DL4*035 allele identified using high-throughput sequencing.","date":"2016","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/26917249","citation_count":1,"is_preprint":false},{"pmid":"40309956","id":"PMC_40309956","title":"Mechanism of microRNA-152 Regulating Decidual Natural Killer Cell Viability and Affecting Trophoblast Cell Invasiveness via the HLA-G/KIR2DL4 Axis.","date":"2025","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40309956","citation_count":0,"is_preprint":false},{"pmid":"35774414","id":"PMC_35774414","title":"Modularisation of published and novel models toward a complex KIR2DL4 pathway in pbNK cell.","date":"2022","source":"MethodsX","url":"https://pubmed.ncbi.nlm.nih.gov/35774414","citation_count":0,"is_preprint":false},{"pmid":"41632833","id":"PMC_41632833","title":"The fetal trophoblast cell marker HLA-G activates a type I interferon response in primary NK cells through the receptor KIR2DL4.","date":"2026","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/41632833","citation_count":0,"is_preprint":false},{"pmid":"29419875","id":"PMC_29419875","title":"[Association of polymorphisms of KIR2DL4 gene with leukemia among ethnic Hans from southern China].","date":"2018","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29419875","citation_count":0,"is_preprint":false},{"pmid":"28397235","id":"PMC_28397235","title":"[Allelic diversity of KIR2DL4 gene and identification of five novel alleles among southern Han Chinese population].","date":"2017","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28397235","citation_count":0,"is_preprint":false},{"pmid":"32823754","id":"PMC_32823754","title":"Quantitative Multiplex Real-Time Reverse Transcriptase-Polymerase Chain Reaction with Fluorescent Probe Detection of Killer Immunoglobulin-Like Receptors, KIR2DL4/3DL3.","date":"2020","source":"Diagnostics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32823754","citation_count":0,"is_preprint":false},{"pmid":"36256498","id":"PMC_36256498","title":"The novel KIR2DL4*00108 allele identified by sequencing-based typing in a Chinese Han individual.","date":"2022","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/36256498","citation_count":0,"is_preprint":false},{"pmid":"31044496","id":"PMC_31044496","title":"Characterization of the novel KIR2DL4*037 allele identified in a Chinese Hani individual.","date":"2019","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/31044496","citation_count":0,"is_preprint":false},{"pmid":"31069992","id":"PMC_31069992","title":"Identification of the novel KIR2DL4*036 allele in a Chinese Hani individual.","date":"2019","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/31069992","citation_count":0,"is_preprint":false},{"pmid":"29577675","id":"PMC_29577675","title":"Identification of the novel KIR2DL4*00106 allele in a southern Chinese Han individual.","date":"2018","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/29577675","citation_count":0,"is_preprint":false},{"pmid":"31070014","id":"PMC_31070014","title":"The novel KIR2DL4*038 allele identified by sequencing-based typing in a Chinese Naxi individual.","date":"2019","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/31070014","citation_count":0,"is_preprint":false},{"pmid":"31041847","id":"PMC_31041847","title":"Description of the novel KIR2DL4*00603 allele identified in a Chinese Hani individual.","date":"2019","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/31041847","citation_count":0,"is_preprint":false},{"pmid":"29292865","id":"PMC_29292865","title":"Description of the novel KIR2DL4*039 allele identified in a southern Chinese Han individual.","date":"2018","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/29292865","citation_count":0,"is_preprint":false},{"pmid":"29316382","id":"PMC_29316382","title":"Identification of the novel KIR2DL4*040 allele in a southern Chinese Han individual.","date":"2018","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/29316382","citation_count":0,"is_preprint":false},{"pmid":"27748071","id":"PMC_27748071","title":"Identification of the novel KIR2DL4*00503 allele from a southern Chinese Han individual.","date":"2016","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/27748071","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.12.25329504","title":"Rare variants in infection response protein pathways associated with sepsis in children","date":"2025-06-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.12.25329504","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.15.648991","title":"VN1K: a genome graph-based and function-driven multi-omics and phenomics resource for the Vietnamese population","date":"2025-04-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.15.648991","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34075,"output_tokens":6564,"usd":0.100343,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15365,"output_tokens":5568,"usd":0.108012,"stage2_stop_reason":"end_turn"},"total_usd":0.208355,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"KIR2DL4 engagement on resting NK cells induces IFN-γ production but not cytotoxicity, and this IFN-γ induction is blocked by a p38 MAPK inhibitor, placing p38 MAPK downstream of KIR2DL4 signaling; in contrast, CD16 and 2B4 induced cytotoxicity but not IFN-γ, revealing a functional dichotomy dictated by individual receptor signals.\",\n      \"method\": \"Redirected lysis assay, cytokine ELISA, pharmacological MAPK inhibitors (p38 vs ERK pathway)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean functional assays with pharmacological pathway dissection, multiple orthogonal readouts in a focused mechanistic study\",\n      \"pmids\": [\"11489965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The transmembrane arginine-tyrosine motif (not the cytoplasmic ITIM) is required for the activating signal of KIR2DL4; the ITIM tyrosine is dispensable for activation but, when phosphorylated, recruits SHP-1 and SHP-2 (Src homology 2-containing phosphatases), conferring inhibitory potential; an activation-deficient KIR2DL4 mutant can inhibit CD16-mediated signaling.\",\n      \"method\": \"Site-directed mutagenesis of ITIM tyrosine and transmembrane arginine; redirected lysis assay; GST pull-down with phosphorylated cytoplasmic tail and SHP-1/SHP-2\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro mutagenesis combined with pull-down biochemistry and functional assay in a single rigorous study\",\n      \"pmids\": [\"12055234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"KIR2DL4 engagement triggers potent IFN-γ production but weak cytotoxicity in NK cells; the ITIM does not influence the activating function of the full-length receptor (2DL4.1), and a truncated form lacking the ITIM (2DL4*) shows similar activation potential, confirming the ITIM is not required for activation.\",\n      \"method\": \"Epitope-tagged receptor transfection into NK-like cell line; antibody cross-linking; cytokine ELISA; redirected lysis assay; comparison of full-length vs. truncated cDNA clones\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cDNA constructs compared with orthogonal functional readouts (cytokine vs. cytotoxicity), single lab\",\n      \"pmids\": [\"14500636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The 9A allele of KIR2DL4 (single adenine deletion in the transmembrane exon causing a frameshift and premature stop codon) results in loss of cell-surface expression; only individuals with at least one 10A allele show detectable surface KIR2DL4 and activating function in redirected lysis assays.\",\n      \"method\": \"Transfection of 10A vs. 9A cDNA into cell lines; surface staining with anti-KIR2DL4 mAb on primary NK cells stratified by genotype; redirected lysis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genotype-phenotype correlation confirmed by both transfection and primary cell analysis, replicated across multiple donors\",\n      \"pmids\": [\"12902476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"KIR2DL4 associates with FcεRI-γ (FcepsilonRI-gamma) via its transmembrane arginine residue; this association promotes surface expression and provides signal-transducing function. Weak cytolytic responses correlate with low stoichiometric association with γ. This distinguishes KIR2DL4 from all other activating KIRs, which associate with DAP12.\",\n      \"method\": \"Co-immunoprecipitation; biochemical association assays; functional cytolysis assays; transmembrane arginine mutagenesis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal biochemical evidence plus functional validation with mutagenesis, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15778339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The KIR2DL4 promoter drives NK cell-specific reporter gene expression. An inhibitory element upstream of the core promoter suppresses KIR2DL4 promoter activity. AML-2 (RUNX family) binds a conserved AML site in the KIR2DL4 promoter and acts as a repressor; mutation of this site increases promoter activity.\",\n      \"method\": \"Promoter-reporter transfection assays in NK3.3 cells and primary NK cells; DNase I footprinting; site-directed mutagenesis of transcription factor binding sites; methyltransferase inhibitor treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter dissection with mutagenesis and footprinting in NK cells, single lab\",\n      \"pmids\": [\"15778373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Residues Met76 and Gln79 in the α1 domain of HLA-G are critical for KIR2DL4 recognition; mutation of both to Ala reduced binding of a KIR2DL4-IgG Fc fusion protein and altered cytolytic function of KIR2DL4-transfected NK-92 cells against HLA-G-expressing targets.\",\n      \"method\": \"Retroviral transduction of wild-type and mutant HLA-G into K562 cells; KIR2DL4-IgG Fc fusion protein binding assay; cytotoxicity (LDH release) assay with KIR2DL4-transfected NK-92 cells\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis of ligand with binding assay and functional cytotoxicity readout, single lab\",\n      \"pmids\": [\"15780179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"KIR2DL4 encoded by the 9A allele can produce a secreted form of the receptor (lacking the transmembrane domain due to exon skipping); individuals with 10A alleles who lack detectable surface KIR2DL4 express a ΔD0 receptor not recognized by available anti-KIR2DL4 mAbs; surface KIR2DL4 disappears 16 days post-activation despite maintained mRNA, indicating a post-transcriptional negative regulator of surface expression.\",\n      \"method\": \"RT-PCR analysis of splice variants; flow cytometry with anti-KIR2DL4 mAbs; in vitro NK cell culture and activation assays; genotyping\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple primary donor analyses with orthogonal methods (flow cytometry, RT-PCR, culture assays), single lab\",\n      \"pmids\": [\"17171757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"KIR2DL4 signals through two distinct structural modules: (1) the transmembrane arginine mediates FcεRI-γ association, which is required for cytolytic activity and calcium responses; (2) a second domain independent of the transmembrane arginine activates MAPKs (JNK, ERK, p38), the classical NF-κB pathway (IKKβ phosphorylation, IκBα degradation), and cytokine transcription/translation (TNF-α, IFN-γ, MIP1α, MIP1β, IL-8). MAPK inhibitors (JNK, MEK1/2, p38) block cytokine production in a nonredundant manner.\",\n      \"method\": \"Site-directed mutagenesis of transmembrane arginine (R/G mutant); receptor cross-linking; Western blot for MAPK phosphorylation and IκBα; pharmacological inhibitors; cytokine ELISA; co-immunoprecipitation for FcεRI-γ\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis plus multiple pathway readouts plus pharmacological dissection in a single rigorous mechanistic study\",\n      \"pmids\": [\"18292514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Epigenetic status of the KIR2DL4 promoter determines transcriptional competency: NK cells have a fully demethylated KIR2DL4 promoter with active histone marks (H3/H4 acetylation, di/trimethyl H3-Lys4, reduced dimethyl H3-Lys9); aging T cells show partial demethylation and increased dimethyl H3-Lys4 that renders the promoter sensitive to DNMT inhibition, enabling KIR2DL4 transcription.\",\n      \"method\": \"Bisulfite sequencing of KIR2DL4 promoter; chromatin immunoprecipitation (ChIP) for histone modifications; DNMT inhibitor treatment; RT-PCR for KIR2DL4 expression in sorted T cell subsets\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus bisulfite sequencing plus functional DNMT inhibition, single lab\",\n      \"pmids\": [\"18586981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"KIR2DL4 resides in endosomes rather than on the cell surface of resting NK cells. Soluble HLA-G is internalized into KIR2DL4-positive endosomes, and signaling from this intracellular location triggers a proinflammatory and proangiogenic response via the serine/threonine kinases DNA-PKcs and Akt.\",\n      \"method\": \"Endosomal fractionation/localization studies; receptor internalization assays; inhibitor studies targeting DNA-PKcs and Akt; cytokine/angiogenic factor readouts (reviewed/summarized mechanistic findings)\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation and localization with functional signaling pathway identification, review article summarizing original experimental findings\",\n      \"pmids\": [\"20854369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CD158d (KIR2DL4) engagement by agonists triggers a DNA damage response pathway (DNA-PKcs, Akt, NF-κB) and induces cellular senescence in NK cells, characterized by p21 upregulation, HP1-γ phosphorylation, morphological enlargement, survival without cell-cycle entry, and a senescence-associated secretory phenotype (SASP). The secretome of CD158d-stimulated senescent NK cells promoted vascular remodeling and angiogenesis (vascular permeability and endothelial tube formation).\",\n      \"method\": \"CD158d agonist stimulation of primary NK cells; Western blot for p21 and phospho-HP1-γ; cell morphology analysis; transcriptional profiling (SASP signature); functional assays for vascular permeability and endothelial cell tube formation; retrospective transcriptome analysis of decidual NK cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (biochemistry, transcriptomics, cell biology, functional vascular assays) in primary cells with mechanistic pathway identification\",\n      \"pmids\": [\"23184984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Transcription factors Runx3 and Ets1 bind the KIR2DL4 promoter in situ and are essential for constitutive 2DL4 transcription; two redundant Runx binding sites and a CRE element are required for basal activity. IL-2/IL-15 stimulation increases 2DL4 promoter activity through functional Runx, CRE, and Ets sites.\",\n      \"method\": \"Promoter mutagenesis; EMSA; cotransfection reporter assays; chromatin immunoprecipitation (ChIP) for Runx3 and Ets1 binding in situ\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis, EMSA, and in situ ChIP confirming transcription factor binding, multiple orthogonal methods in one study\",\n      \"pmids\": [\"22467658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"KIR2DL4 directly interacts with heparan sulfate (HS)/heparin via its D0 domain (identified by genome-wide siRNA screen revealing HS3ST3B1 as a regulator); HS/heparin regulates KIR2DL4-mediated cytokine production; exogenous HS/heparin induces differential KIR2DL4 localization to Rab5+ and Rab7+ endosomes leading to cytokine downregulation and receptor degradation. Syndecan-4 (SDC4) HSPG directly interacts with KIR2DL4 and affects receptor endocytosis and membrane trafficking.\",\n      \"method\": \"Genome-wide high-throughput siRNA screen; direct binding assays (KIR2DL4–HS/heparin); D0 domain deletion mutant analysis; cytokine ELISA; confocal microscopy for Rab5+/Rab7+ endosomal localization; co-immunoprecipitation (KIR2DL4–syndecan-4)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide unbiased screen followed by direct binding assays, domain mutagenesis, subcellular localization, and functional cytokine readouts\",\n      \"pmids\": [\"24127555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of the KIR2DL4 extracellular domains resolved at 2.8 Å reveals a D0-D2 arrangement (no D1 domain) with C2-type immunoglobulin folds and an acute elbow angle. KIR2DL4 self-associates via the D0 domain in a concentration-dependent manner, forming a tetramer in the crystal lattice confirmed by size exclusion chromatography, dynamic light scattering, analytical ultracentrifugation, and SAXS. D0 residues required for tetramer formation preclude an HLA-binding mode akin to KIR3DL1; no direct HLA interaction was detected in binding studies.\",\n      \"method\": \"X-ray crystallography (2.8 Å); size exclusion chromatography; dynamic light scattering; analytical ultracentrifugation; small-angle X-ray scattering (SAXS); direct HLA binding studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure validated by four independent biophysical techniques, rigorous mechanistic conclusions about self-association and HLA binding\",\n      \"pmids\": [\"25759384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"KIR2DL4 forms a regulatory circuit with the IFN-γ pathway: IFN-γ upregulates KIR2DL4 expression via JAK2/STAT1 signaling, and KIR2DL4 in turn synergizes with Fcγ receptor to increase IFN-γ secretion by NK cells. HLA-G binding to KIR2DL4 desensitizes NK cells to trastuzumab by disrupting antibody-dependent cell-mediated cytotoxicity (ADCC). Blockade of HLA-G/KIR2DL4 signaling restored NK cell cytotoxicity against HER2+ breast cancer in vivo.\",\n      \"method\": \"Co-culture assays; NK cell cytotoxicity assays; JAK2/STAT1 pathway inhibition; anti-KIR2DL4/HLA-G blocking antibodies; in vivo xenograft mouse model; cytokine ELISA (IFN-γ, TGF-β)\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional pathway dissection with pathway inhibitors and in vivo model, single lab\",\n      \"pmids\": [\"34158475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"KIR2DL4 expressed on NK cells interacts with HLA-G expressed on oligodendrocytes; this KIR2DL4–HLA-G interaction is required for NK-cell-mediated IFN-γ polarization toward oligodendrocytes, which in turn reduces myelin oligodendrocyte glycoprotein (MOG) and myelin associated glycoprotein (MAG) content. This activity is independent of KIR2DL1-mediated MHC class I inhibition.\",\n      \"method\": \"NK cell–oligodendrocyte conjugate assay; intracellular cytokine staining for IFN-γ; anti-KIR2DL4 blocking antibody; Western blot for MOG and MAG; flow cytometry for KIR2DL4+ NK cell frequency\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — blocking antibody epistasis experiment with functional protein-level readouts, single lab\",\n      \"pmids\": [\"30482463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"KIR2DL4 is expressed on human mast cells (peripheral blood-derived and LAD2 cell line). Agonistic antibodies to KIR2DL4 negatively regulate KIT-mediated and FcεRI-mediated mast cell responses. HLA-G (natural KIR2DL4 ligand) and agonistic antibodies induce secretion of leukemia inhibitory factor and serine proteases from human mast cells.\",\n      \"method\": \"Flow cytometry for KIR2DL4 on mast cells; agonistic anti-KIR2DL4 antibody stimulation; functional assays for KIT-mediated and FcεRI-mediated responses; ELISA for leukemia inhibitory factor and serine proteases\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — clean functional assays in both primary cells and cell line with defined receptor manipulation, single lab\",\n      \"pmids\": [\"32023940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"KIR2DL4 is expressed in renal cell carcinoma (RCC) cells and promotes RCC cell proliferation; knockdown reduces proliferation/viability while overexpression promotes it in vitro and in vivo. The mechanism involves activation of the PI3K/Akt signaling pathway, as AKT phosphorylation levels correlate with KIR2DL4 expression levels, and combined PI3K inhibitor (wortmannin) plus KIR2DL4-shRNA further reduces phospho-AKT and proliferation.\",\n      \"method\": \"MTT viability assay; soft agar colony formation; KIR2DL4 knockdown (shRNA) and overexpression; xenograft mouse model; RNA sequencing; Western blot for phospho-AKT; PI3K inhibitor (wortmannin) treatment\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO/OE with in vitro and in vivo readouts plus RNA-seq and pharmacological pathway confirmation, single lab\",\n      \"pmids\": [\"35063466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Soluble HLA-G activates transcription of type I interferon-stimulated genes (ISGs) in primary NK cells through KIR2DL4 via a noncanonical pathway requiring transcription factor IRF7 and kinase JAK1. The C-terminal portion of the KIR2DL4 cytoplasmic tail contains a sequence analogous to conserved JAK1 binding sites in IFN receptors and is required for JAK1 binding to KIR2DL4. HLA-G stimulation leads to nuclear phosphorylation of IRF7 and JAK substrate STAT2, linking KIR2DL4 signaling to ISG transcription. scRNA-seq showed HLA-G induces a broader response in CD56bright than CD56dim NK cells, and ISG expression was detected at the early maternal-fetal interface.\",\n      \"method\": \"Primary NK cell stimulation with soluble HLA-G vs. agonistic anti-KIR2DL4 antibody; RNA-seq and scRNA-seq; pharmacological JAK1 inhibition; cytoplasmic tail mutagenesis/deletion constructs; co-immunoprecipitation (KIR2DL4–JAK1); Western blot for nuclear phospho-IRF7 and phospho-STAT2; comparison with decidual NK scRNA-seq dataset\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis, co-IP, pharmacological inhibition, nuclear phosphorylation detection, and transcriptomic validation in primary cells with multiple orthogonal methods\",\n      \"pmids\": [\"41632833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In decidual NK (dNK) cells, KIR2DL4 surface expression is controlled by the 9A/10A transmembrane polymorphism (as in peripheral blood NK cells). Freshly isolated dNK cells do not secrete IFN-γ in response to KIR2DL4 ligation regardless of genotype, but IL-2 activation in vitro enables IFN-γ secretion only in donors with at least one 10A allele.\",\n      \"method\": \"Flow cytometry for KIR2DL4 surface expression on freshly isolated decidual NK cells; anti-KIR2DL4 ligation; IFN-γ ELISA; genotyping for 9A/10A polymorphism\",\n      \"journal\": \"Molecular human reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct functional assay on primary decidual NK cells stratified by genotype, single lab\",\n      \"pmids\": [\"19509110\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KIR2DL4 (CD158d) is an endosome-resident NK cell receptor with a unique D0-D2 extracellular structure that self-associates via D0; it signals through two structural modules—a transmembrane arginine that recruits FcεRI-γ (mediating cytotoxicity/calcium responses) and a second receptor domain that independently activates MAPKs and NF-κB for cytokine production—with soluble HLA-G binding triggering endosomal signaling via DNA-PKcs, Akt, NF-κB, and a noncanonical JAK1-IRF7-STAT2 pathway that drives type I interferon-stimulated gene transcription; the cytoplasmic ITIM can recruit SHP-1/SHP-2 when phosphorylated (conferring inhibitory potential), its expression is regulated epigenetically by promoter methylation and by Runx3/Ets1 transcription factors, and its 9A/10A allelic polymorphism determines whether a membrane-anchored or secreted receptor is produced; additional ligands include heparan sulfate proteoglycans (via the D0 domain), and KIR2DL4 signaling can induce NK cell senescence with a proangiogenic secretory phenotype relevant to vascular remodeling at the maternal-fetal interface, as well as PI3K/Akt-dependent proliferative signaling in renal cell carcinoma cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"KIR2DL4 (CD158d) is an NK-cell receptor that, unlike its inhibitory KIR relatives, principally drives cytokine production rather than cytotoxicity, inducing IFN-\\u03b3 and other proinflammatory mediators through MAPK- and NF-\\u03baB-dependent signaling [#0, #8]. It signals through two structurally separable modules: a transmembrane arginine that recruits the Fc\\u03b5RI-\\u03b3 adaptor to support cytolytic and calcium responses, and a second arginine-independent module that activates JNK, ERK, p38, and the IKK\\u03b2\\u2013I\\u03baB\\u03b1\\u2013NF-\\u03baB axis to drive cytokine transcription [#4, #8]. Its cytoplasmic ITIM is dispensable for activation but, when phosphorylated, recruits SHP-1 and SHP-2 to confer inhibitory potential [#1]. KIR2DL4 resides predominantly in endosomes of resting NK cells, where internalized soluble HLA-G triggers signaling via DNA-PKcs, Akt, and NF-\\u03baB, and through a noncanonical JAK1\\u2013IRF7\\u2013STAT2 cascade\\u2014JAK1 binding to an IFN-receptor-like sequence in the cytoplasmic tail\\u2014that drives type I interferon-stimulated gene transcription [#10, #19]. The crystal structure reveals an unusual D0\\u2013D2 architecture that self-associates into tetramers through the D0 domain, the same domain that binds heparan sulfate proteoglycans and syndecan-4 to modulate endosomal trafficking and cytokine output [#13, #14]. Engagement induces an NK-cell senescence program with a proangiogenic secretory phenotype relevant to vascular remodeling at the maternal-fetal interface [#11]. Expression is governed by 9A/10A transmembrane polymorphism determining membrane versus secreted receptor [#3, #7], by promoter DNA methylation and histone marks, and by Runx3/Ets1 transcription factors [#9, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that KIR2DL4 engagement uncouples cytokine production from cytotoxicity, defining it as a functionally distinct NK receptor whose signal selectively drives IFN-\\u03b3 via p38 MAPK.\",\n      \"evidence\": \"Redirected lysis and cytokine ELISA with pharmacological MAPK inhibitors on resting NK cells\",\n      \"pmids\": [\"11489965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the membrane adaptor or proximal signaling module\", \"Mechanism of selective IFN-\\u03b3 induction unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapped the activating signal to a transmembrane arginine-tyrosine motif and showed the ITIM is dispensable for activation but recruits SHP-1/SHP-2 when phosphorylated, defining a dual activating/inhibitory potential.\",\n      \"evidence\": \"Site-directed mutagenesis, GST pull-down with phospho-tail, redirected lysis\",\n      \"pmids\": [\"12055234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the transmembrane-associated adaptor not yet defined\", \"Physiological conditions favoring inhibitory vs activating output unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Confirmed the ITIM is not required for the activating function across full-length and truncated isoforms, and showed the 9A frameshift allele abolishes surface expression, linking allelic polymorphism to receptor availability.\",\n      \"evidence\": \"cDNA construct comparison, surface staining of genotype-stratified primary NK cells, redirected lysis\",\n      \"pmids\": [\"14500636\", \"12902476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fate of the 9A transcript product not characterized at this stage\", \"Post-transcriptional control of surface expression not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified Fc\\u03b5RI-\\u03b3 as the adaptor recruited via the transmembrane arginine, distinguishing KIR2DL4 from DAP12-associated activating KIRs, and located the HLA-G recognition determinants and a RUNX-based promoter repressor.\",\n      \"evidence\": \"Co-IP and mutagenesis for Fc\\u03b5RI-\\u03b3; HLA-G \\u03b11 mutagenesis with Fc-fusion binding and cytotoxicity; promoter reporter, footprinting, and AML-2 site mutation\",\n      \"pmids\": [\"15778339\", \"15780179\", \"15778373\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of \\u03b3 association versus signaling output incompletely defined\", \"Later structural work questioned direct HLA-G binding\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved isoform complexity by showing the 9A allele yields a secreted receptor and that surface expression is lost post-activation despite stable mRNA, revealing post-transcriptional control of surface display.\",\n      \"evidence\": \"RT-PCR of splice variants, flow cytometry, in vitro NK activation, genotyping\",\n      \"pmids\": [\"17171757\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the post-transcriptional negative regulator unknown\", \"Function of the secreted/\\u0394D0 forms not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined two structurally separable signaling modules\\u2014arginine/Fc\\u03b5RI-\\u03b3 for cytolysis and calcium, and an arginine-independent module for MAPK/NF-\\u03baB-driven cytokine production\\u2014and showed transcriptional licensing depends on promoter methylation and histone state.\",\n      \"evidence\": \"Arginine mutagenesis, Western blot for MAPK/I\\u03baB\\u03b1, pharmacological inhibitors, cytokine ELISA; bisulfite sequencing and ChIP for histone marks\",\n      \"pmids\": [\"18292514\", \"18586981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the second signaling module's proximal effector unclear\", \"How the two modules are coordinately engaged by ligand not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended the 9A/10A genotype-phenotype relationship to decidual NK cells and showed IL-2 activation is required to license IFN-\\u03b3 responses in 10A donors, linking receptor function to the tissue context.\",\n      \"evidence\": \"Flow cytometry, anti-KIR2DL4 ligation, IFN-\\u03b3 ELISA on genotyped decidual NK cells\",\n      \"pmids\": [\"19509110\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of IL-2-dependent licensing not defined\", \"Endogenous decidual ligand engagement not directly demonstrated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Relocalized the receptor's signaling platform to endosomes, showing soluble HLA-G is internalized and signals from this intracellular compartment via DNA-PKcs and Akt to a proinflammatory/proangiogenic output.\",\n      \"evidence\": \"Endosomal fractionation, internalization assays, DNA-PKcs/Akt inhibitor studies\",\n      \"pmids\": [\"20854369\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review summary of original data\", \"How endosomal targeting selects signaling output not detailed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected endosomal KIR2DL4 signaling to a DNA-damage-response-driven NK senescence program with a proangiogenic secretome relevant to maternal-fetal vascular remodeling, and defined Runx3/Ets1 as essential activators of constitutive transcription.\",\n      \"evidence\": \"CD158d agonist stimulation, p21/phospho-HP1-\\u03b3 Westerns, SASP profiling, vascular permeability and tube formation assays; promoter mutagenesis, EMSA, ChIP for Runx3/Ets1\",\n      \"pmids\": [\"23184984\", \"22467658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution to placentation not directly established\", \"Link between senescence induction and the two signaling modules unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified heparan sulfate proteoglycans, including syndecan-4, as D0-domain ligands that direct receptor trafficking to Rab5/Rab7 endosomes and tune cytokine output and degradation.\",\n      \"evidence\": \"Genome-wide siRNA screen (HS3ST3B1), direct binding assays, D0 deletion mutants, confocal Rab5/Rab7 localization, KIR2DL4\\u2013syndecan-4 co-IP, cytokine ELISA\",\n      \"pmids\": [\"24127555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative physiological roles of HSPG versus HLA-G ligation unclear\", \"Whether HSPG binding initiates signaling or only modulates trafficking not fully resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Determined the extracellular structure as a D0\\u2013D2 arrangement that self-associates into D0-mediated tetramers and showed D0 residues required for oligomerization preclude a classical HLA-binding mode, challenging direct HLA-G recognition.\",\n      \"evidence\": \"2.8 \\u00c5 crystal structure validated by SEC, DLS, AUC, SAXS, and direct HLA binding studies\",\n      \"pmids\": [\"25759384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with prior HLA-G functional data not achieved\", \"Functional consequence of tetramerization for signaling not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated a non-canonical functional context in which NK KIR2DL4 engaging oligodendrocyte HLA-G drives IFN-\\u03b3 polarization that reduces myelin protein content, independent of KIR2DL1-mediated MHC inhibition.\",\n      \"evidence\": \"NK-oligodendrocyte conjugate assay, intracellular IFN-\\u03b3 staining, anti-KIR2DL4 blockade, MOG/MAG Westerns\",\n      \"pmids\": [\"30482463\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling module responsible not dissected\", \"In vivo relevance to demyelinating disease not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed KIR2DL4 expression and function extend beyond NK cells to mast cells, where agonism modulates KIT- and Fc\\u03b5RI-mediated responses and induces secretion of LIF and serine proteases.\",\n      \"evidence\": \"Flow cytometry and agonistic antibody stimulation of primary and LAD2 mast cells, functional response assays, ELISA\",\n      \"pmids\": [\"32023940\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway in mast cells not mapped\", \"Physiological mast-cell ligand context not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a feed-forward circuit in which IFN-\\u03b3 upregulates KIR2DL4 via JAK2/STAT1 and KIR2DL4 synergizes with Fc\\u03b3R for IFN-\\u03b3 secretion, and showed HLA-G/KIR2DL4 engagement suppresses ADCC against HER2+ tumors that blockade restores.\",\n      \"evidence\": \"Co-culture and cytotoxicity assays, JAK2/STAT1 inhibition, blocking antibodies, xenograft model, cytokine ELISA\",\n      \"pmids\": [\"34158475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab in vivo model\", \"Mechanism by which HLA-G ligation desensitizes ADCC not fully resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed an intrinsic tumor-cell role for KIR2DL4 in renal cell carcinoma, promoting proliferation through PI3K/Akt signaling, distinct from its immune-receptor function.\",\n      \"evidence\": \"shRNA knockdown and overexpression, MTT and soft agar assays, xenograft, RNA-seq, phospho-AKT Westerns, wortmannin treatment\",\n      \"pmids\": [\"35063466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream ligand/activation in tumor cells unknown\", \"Single-lab finding in one cancer type\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Resolved a non-canonical interferon-like signaling mechanism in which the KIR2DL4 cytoplasmic tail binds JAK1 through an IFN-receptor-like sequence and, upon soluble HLA-G binding, drives IRF7/STAT2 nuclear phosphorylation and type I ISG transcription, preferentially in CD56bright NK cells.\",\n      \"evidence\": \"Soluble HLA-G vs agonist stimulation, RNA-seq/scRNA-seq, JAK1 inhibition, tail mutagenesis, KIR2DL4\\u2013JAK1 co-IP, nuclear phospho-IRF7/STAT2 Westerns\",\n      \"pmids\": [\"41632833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How JAK1\\u2013IRF7\\u2013STAT2 integrates with the MAPK/NF-\\u03baB and DNA-PKcs/Akt arms unclear\", \"In vivo function of ISG induction at the maternal-fetal interface not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the structurally distinct signaling modules (Fc\\u03b5RI-\\u03b3/cytolytic, MAPK/NF-\\u03baB cytokine, DNA-PKcs/Akt senescence, JAK1/IRF7/STAT2 interferon) and the multiple ligands (HLA-G, HSPGs) are coordinately selected to produce a given functional outcome.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking ligand identity, endosomal localization, and output module\", \"Reconciliation of structural absence of HLA-G binding with functional HLA-G responses unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 8, 19]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [6, 19]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 1]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [10, 13]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 8, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 10, 19]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FCER1G\", \"HLA-G\", \"PTPN6\", \"PTPN11\", \"SDC4\", \"JAK1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}